173 related articles for article (PubMed ID: 38062199)
1. A pan-cancer analysis of anti-proliferative protein family genes for therapeutic targets in cancer.
Zhang S; Gu J; Shi LL; Qian B; Diao X; Jiang X; Wu J; Wu Z; Shen A
Sci Rep; 2023 Dec; 13(1):21607. PubMed ID: 38062199
[TBL] [Abstract][Full Text] [Related]
2. Expression and prognosis analyses of the Tob/BTG antiproliferative (APRO) protein family in human cancers.
Bai Y; Qiao L; Xie N; Shi Y; Liu N; Wang J
PLoS One; 2017; 12(9):e0184902. PubMed ID: 28922388
[TBL] [Abstract][Full Text] [Related]
3. Pan-cancer evidence of prognosis, immune infiltration, and immunotherapy efficacy for annexin family using multi-omics data.
Shen C; Zhang S; Zhang Z; Yang S; Zhang Y; Lin Y; Fu C; Li Z; Wu Z; Wang Z; Li Z; Guo J; Li P; Hu H
Funct Integr Genomics; 2023 Jun; 23(3):211. PubMed ID: 37358720
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
[TBL] [Abstract][Full Text] [Related]
5. Up-regulation of the BTG2 gene in TPA- or RA-treated HL-60 cell lines.
Cho BO; Jeong YW; Kim SH; Park K; Lee JH; Kweon GR; Park JC
Oncol Rep; 2008 Mar; 19(3):633-7. PubMed ID: 18288394
[TBL] [Abstract][Full Text] [Related]
6. A conserved motif in human BTG1 and BTG2 proteins mediates interaction with the poly(A) binding protein PABPC1 to stimulate mRNA deadenylation.
Amine H; Ripin N; Sharma S; Stoecklin G; Allain FH; Séraphin B; Mauxion F
RNA Biol; 2021 Dec; 18(12):2450-2465. PubMed ID: 34060423
[TBL] [Abstract][Full Text] [Related]
7. Pan-cancer analyses of clinical prognosis, immune infiltration, and immunotherapy efficacy for TRPV family using multi-omics data.
Shen C; Fu C; Suo Y; Li K; Zhang Z; Yang S; Zhang Y; Lin Y; Li Z; Wu Z; Huang S; Chen H; Fan Z; Hu H
Heliyon; 2023 Jun; 9(6):e16897. PubMed ID: 37346342
[TBL] [Abstract][Full Text] [Related]
8. Pan-cancer analysis reveals interleukin-17 family members as biomarkers in the prediction for immune checkpoint inhibitor curative effect.
Han X; Ye J; Huang R; Li Y; Liu J; Meng T; Song D
Front Immunol; 2022; 13():900273. PubMed ID: 36159856
[TBL] [Abstract][Full Text] [Related]
9. A pan-cancer analysis of the HER family gene and their association with prognosis, tumor microenvironment, and therapeutic targets.
Yang X; Miao Y; Wang J; Mi D
Life Sci; 2021 May; 273():119307. PubMed ID: 33691171
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the role of Frizzled 2 in different cancer types.
Zhou M; Sun X; Zhu Y
FEBS Open Bio; 2021 Apr; 11(4):1195-1208. PubMed ID: 33565732
[TBL] [Abstract][Full Text] [Related]
11. A comprehensive analysis of gasdermin family gene as therapeutic targets in pan-cancer.
Huo CL; Deng Y; Sun ZG
Sci Rep; 2022 Aug; 12(1):13329. PubMed ID: 35922531
[TBL] [Abstract][Full Text] [Related]
12. Pan-cancer analysis identifies RNF43 as a prognostic, therapeutic and immunological biomarker.
Xu Y; Lin Z; Ji Y; Zhang C; Tang X; Li C; Liu T
Eur J Med Res; 2023 Oct; 28(1):438. PubMed ID: 37848933
[TBL] [Abstract][Full Text] [Related]
13. Pan-cancer analysis of N4-acetylcytidine adaptor THUMPD1 as a predictor for prognosis and immunotherapy.
Li K; Liu J; Yang X; Tu Z; Huang K; Zhu X
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34762107
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive Analysis of
Liu J; Zhu B; Chen J; Cao Y
Anticancer Res; 2023 Oct; 43(10):4491-4509. PubMed ID: 37772558
[TBL] [Abstract][Full Text] [Related]
15. In search of a function for the TIS21/PC3/BTG1/TOB family.
Matsuda S; Rouault J; Magaud J; Berthet C
FEBS Lett; 2001 May; 497(2-3):67-72. PubMed ID: 11377414
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of the expression profile and clinical implications of regulator of chromosome condensation 2 in pan-cancers.
Li X; Kang K; Peng Y; Shen L; Shen L; Zhou Y
Aging (Albany NY); 2022 Nov; 14(22):9221-9242. PubMed ID: 36441563
[TBL] [Abstract][Full Text] [Related]
17. A pan-cancer study of class-3 semaphorins as therapeutic targets in cancer.
Zhang X; Klamer B; Li J; Fernandez S; Li L
BMC Med Genomics; 2020 Apr; 13(Suppl 5):45. PubMed ID: 32241267
[TBL] [Abstract][Full Text] [Related]
18. Pan-cancer analysis of SYNGR2 with a focus on clinical implications and immune landscape in liver hepatocellular carcinoma.
Liu C; Qu Z; Zhao H; Wang P; Zhan C; Zhang Y
BMC Bioinformatics; 2023 May; 24(1):192. PubMed ID: 37170221
[TBL] [Abstract][Full Text] [Related]
19. Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy.
Zhang J; Wang K; Hainisayimu T; Li H
Oxid Med Cell Longev; 2022; 2022():9614819. PubMed ID: 36046686
[TBL] [Abstract][Full Text] [Related]
20. The prognostic value and immunological role of CD44 in pan-cancer study.
Chen S; Zhang S; Chen S; Ma F
Sci Rep; 2023 Apr; 13(1):7011. PubMed ID: 37117249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
